Programmed cell death ligand-1 expression in gastroentero-pancreatic neuroendocrine tumors

Simple item page
dc.contributor.authorOktay, E
dc.contributor.authorYalcin, GD
dc.contributor.authorEkmekci, S
dc.contributor.authorKahraman, DS
dc.contributor.authorYalcin, A
dc.contributor.authorDegirmenci, M
dc.contributor.authorDirican, A
dc.contributor.authorAltin, Z
dc.contributor.authorOzdemir, O
dc.contributor.authorSurmeli, Z
dc.contributor.authorDiniz, G
dc.contributor.authorAyhan, S
dc.contributor.authorBulut, G
dc.contributor.authorErdogan, A
dc.contributor.authorUslu, R
dc.date.accessioned2024-07-18T12:06:12Z
dc.date.available2024-07-18T12:06:12Z
dc.description.abstractPurpose: Gastroenteropancreatic tumors (GEPNETs) is a heterogeneous disease with variable clinical course. While promising therapeutic options exist for other adult cancers, there are no new molecular-based treatments developed for GEPNETs. One of the main targets of cancer immunotherapy is the Programmed Cell Death Ligand-1 (PD-L1) pathway. Our purpose was to investigate the profile of PD-L1 expression in different organs of GEPNETs and compare the conventional immunohistochemistry (IHC) with the RNA expression analysis via real time polymerase chain reaction (RT-PCR) in order to determine which patients might be appropriate for immune check point-targeted therapy. Methods: A total of 59 surgically or endoscopically resected GEPNET tissues were retrospectively collected. The expression of PD-LI and mRNA was evaluated with IHC. Results: The expression of PD-L1 was significantly associated with the high-grade classification (p=0.012). PD-LI mRNA expression in tumor samples appeared to be higher compared to the corresponding normal tissues. In appendix, stomach and small intestine, the expression of PD-L1 mRNA was higher in the tumor tissues compared to the respective controls. In pancreas and colon, control tissues tend to have a higher PD-L1 mRNA expression compared to tumor tissues. PD-L1 mRNA expression was higher in GEP carcinomas (p=0.0031). Conclusion: RT-PCR was found to be more sensitive in detecting PD-L1 expression than conventional IHC. This study may provide an important starting point and useful background information for future research about immunotherapy for appendix, stomach and small intestine neuroendocrine carcinomas.
dc.identifier.issn1107-0625
dc.identifier.other2241-6293
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10259
dc.language.isoEnglish
dc.publisherIMPRIMATUR PUBLICATIONS
dc.subjectNIVOLUMAB PLUS IPILIMUMAB
dc.subjectPD-L1 EXPRESSION
dc.subjectPDL1 EXPRESSION
dc.subjectSURVIVAL
dc.subjectCANCER
dc.subjectCLASSIFICATION
dc.subjectEPIDEMIOLOGY
dc.subjectINTERFERONS
dc.subjectMANAGEMENT
dc.subjectPROGNOSIS
dc.titleProgrammed cell death ligand-1 expression in gastroentero-pancreatic neuroendocrine tumors
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu